Therapeutic strategies in extrinsic atopic dermatitis: focus on inhibition of IL-4 as a new pharmacological approach

Bibliography

• Gittler JK, Shemer A, Suarez-Farinas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol 2012;130:1344-54
   PubMed Web of Science ®Google Scholar
• Naldi L, Parazzini F, Gallus S. Prevalence of atopic dermatitis in Italian schoolchildren: factors affecting its variation. Acta Derm Venereol 2009;89:122-5
   Google Scholar
• DaVeiga SP. Epidemiology of atopic dermatitis: a review. Allergy Asthma Proc 2012;33:227-34
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Ellis CN, Mancini AJ, et al. Atopic dermatitis: epidemiology and pathogenesis update. Semin Cutan Med Surg 2012;31(3 suppl):S3-5
   Google Scholar
• Deckers IA, McLean S, Linssen S, et al. Investigating international time trends in the incidence and prevalence of atopic eczema. 1990-2010: a systematic review of epidemiological studies. PLoS One 2012;7:e39803
   PubMed Web of Science ®Google Scholar
• Leung DY. New insights into atopic dermatitis: role of skin barrier and immune dysregulation. Allergol Int 2013;62:151-61
   PubMed Web of Science ®Google Scholar
• Elias PM, Schmuth M. Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr Allergy Asthma Rep 2009;9:265-72
   PubMed Web of Science ®Google Scholar
• Bieber T. Atopic dermatitis. N Engl J Med 2008;358:1483-94
   PubMed Web of Science ®Google Scholar
• Elias PM, Feingold KR. Does the tail wag the dog? Role of the barrier in the pathogenesis of inflammatory dermatoses and therapeutic implications. Arch Dermatol 2001;137:1079-81
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis – part II: immune cell subsets and therapeutic concepts. J Allergy Clin Immunol 2011;127:1420-32
   PubMed Web of Science ®Google Scholar
• Leung DY, Boguniewicz M, Howell MD, et al. New insights into atopic dermatitis. J Clin Invest 2004;113:651-7
   PubMed Web of Science ®Google Scholar
• Katsarou A, Armenaka M. Atopic dermatitis in older patients: particular points. J Eur Acad Dermatol Venereol 2011;25(1):12-18
   PubMed Web of Science ®Google Scholar
• Ozkaya E. Adult-onset atopic dermatitis. J Am Acad Dermatol 2005;52:579-82
   PubMed Web of Science ®Google Scholar
• Novak N, Bieber T. Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol 2003;112:252-62
   PubMed Web of Science ®Google Scholar
• Rhodes HL, Sporik R, Thomas P, et al. Early life risk factors for adult asthma: a birth cohort study of subjects at risk. J Allergy Clin Immunol 2001;108:720-5
   PubMed Web of Science ®Google Scholar
• Lan S, Nickel R, Niggemann B, et al. The development of childhood asthma: lessons from the German Multicentre Allergy Study (MAS). Paediatr Respir Rev 2002;3:265-72
   Google Scholar
• Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003;112:S118-27
   PubMed Web of Science ®Google Scholar
• Simpson EL, Eichenfield LF, Ellis CN, et al. Current issues in atopic comorbidities and preventing the atopic march. Semin Cutan Med Surg 2012;31:S6-9
   Google Scholar
• Kiken DA, Silverberg NB. Atopic Dermatitis in Children, Part 1: epidemiology, Clinical Features, and Complications. Cutis 2006;78:241-7
   PubMed Web of Science ®Google Scholar
• de Bruin Weller MS, Rockmann H, Knulst AC, Bruijnzeel-Koomen CA. Evaluation of the adult patient with atopic dermatitis. Clin Exp Allergy 2013;43:279-91
   Google Scholar
• Ellis CN, Mancini AJ, Paller AS, et al. Understanding and managing atopic dermatitis in adult patients. Semin Cutan Med Surg 2012;31:S18-22
   Google Scholar
• Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol 2012;26:1176-93
   PubMed Web of Science ®Google Scholar
• Deleuran MS, Vestergaard C. Therapy of severe atopic dermatitis in adults. J Dtsch Dermatol Ges 2012;10:399-406
   Google Scholar
• Schram ME, Roekevisch E, Leeflang MM, et al. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol 2011;128:353-9
   PubMed Web of Science ®Google Scholar
• Haeck IM, Knol MJ, Ten Berge O, et al. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol 2011;64:1074-84
   PubMed Web of Science ®Google Scholar
• Darsow U, Wollenberg A, Simon D, et al. Difficult to control atopic dermatitis. World Allergy Organ J 2013;6:6
   PubMedGoogle Scholar
• Oldhoff JM, Darsow U, Werfel T, et al. Anti-IL-5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of atopic dermatitis. Allergy 2005;60:693-6
   PubMed Web of Science ®Google Scholar
• Belloni B, Ziai M, Lim A, et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J All Clini Immunol 2007;120:1223-5
   PubMed Web of Science ®Google Scholar
• Simon D, Hosli S, Kostylina G, et al. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008;121:122-8
   PubMed Web of Science ®Google Scholar
• Ponte P, Lopes MJ. Apparent safe use of single dose rituximab for recalcitrant atopic dermatitis in the first trimester of a twin pregnancy. J Am Acad Dermatol 2010;63:355-6
   PubMed Web of Science ®Google Scholar
• Sánchez-Ramón S, Eguíluz-Gracia I, Rodríguez-Mazariego ME, et al. Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis. J Investig Allergol Clin Immunol 2013;23:190-6
   PubMed Web of Science ®Google Scholar
• Navarini AA, French LE, Hofbauer DF. Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection. J All Clin Immunol 2011;128:1128-30
   PubMed Web of Science ®Google Scholar
• Bao L, Shi VY, Chan LS. IL-4 up-regulates epidermal chemotactic, angiogenic, and pro-inflammatory genes and down-regulates antimicrobial genes in vivo and in vitro: relevant in the pathogenesis of atopic dermatitis. Cytokine 2013;61:419-25
   PubMed Web of Science ®Google Scholar
• Rodriguez E, Baurecht H, Herberich E, et al. Meta-analysis of filaggrin polymorphisms in eczema and asthma: robust risk factors in atopic disease. J Allergy Clin Immunol 2009;123:1361-70
   PubMed Web of Science ®Google Scholar
• Irvine AD. Fleshing out filaggrin phenotypes. J Invest Dermatol 2007;127:504-7
   PubMed Web of Science ®Google Scholar
• Hershey GK, Friedrich MF, Esswein LA, et al. The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N Engl J Med 1997;337:1720-5
   PubMed Web of Science ®Google Scholar
• Ring J, Möhrenschlager M, Weidinger S. Molecular genetics of atopic eczema. 2012;96:24-9
   Google Scholar
• Chien YH, Hwu WL, Chiang BL. The genetics of atopic dermatitis. Clin Rev Allergy Immunol 2007;33:178-90
   PubMed Web of Science ®Google Scholar
• Herberth G, Heinrich J, Röder S, et al. Reduced IFN-gamma- and enhanced IL-4-producing CD4+ cord blood T cells are associated with a higher risk for atopic dermatitis Pediatr Allergy Immunol. 2010;21:5-13
   Google Scholar
• Furue M, Ogata F, Ootsuki M, Ishibashi Y. Hyperresponsibility to exogeneous interleukin 4 in atopic dermatitis. J Dermatol 1989;16:247-50
   Google Scholar
• Okudaira H, Mori A, Akiyoshi K, et al. Interleukin-4 gene expression and IgE responsiveness. Int Arch Allergy Appl Immunol 1991;94:184-6
   Google Scholar
• Reinhold U, Kukel S, Goeden B, et al. Interleukin-4 promotes the expansion of skin-infiltrating lymphocytes from atopic dermatitis in vitro. J Invest Dermatol 1991;96:370-5
   Google Scholar
• Dubois GR, Bruijnzeel-Koomen CA, Bruijnzeel PL. IL-4 induces chemotaxis of blood eosinophils from atopic dermatitis patients, but not from normal individuals. J Invest Dermatol 1994;102:843-6
   Google Scholar
• Moser R, Fehr J, Bruijnzeel PL. IL-4 controls the selective endothelium-driven transmigration of eosinophils from allergic individuals. J Immunol 1992;149:1432-8
   PubMed Web of Science ®Google Scholar
• Renz H, Jujo K, Bradley KL, et al. Enhanced IL-4 production and IL-4 receptor expression in atopic dermatitis and their modulation by interferon-gamma. J Invest Dermatol 1992;99:403-8
   PubMed Web of Science ®Google Scholar
• Hamid Q, Boguniewicz M, Leung DY. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 1994;94:870-6
   PubMed Web of Science ®Google Scholar
• Hamid Q, Naseer T, Minshall EM, et al. In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol 1996;98:225-31
   PubMed Web of Science ®Google Scholar
• Gahr N, Fölster-Holst R, Weichenthal M, et al. Dermal fibroblasts from acute inflamed atopic dermatitis lesions display increased eotaxin/CCL11 responsiveness to inteleukin-4 stimulation. Br J Dermatol 2011;164:586-92
   Google Scholar
• Bao L, Shi VY, Chan LS. IL-4 regulates chemokine CCL26 in keratinocytes through the Jak1, 2/Stat6 signal transduction pathway: implication for atopic dermatitis. Mol Immunol 2012;50:91-7
   PubMed Web of Science ®Google Scholar
• Seneviratne SL, Black AP, Jones L, et al. Interleukin-4 promotes human CD8 T cell expression of CCR7. Immunology 2007;120:66-72
   Google Scholar
• Novak H, Müller A, Harrer N, et al. CCL23 expression is induced by IL-4 in a STAT6-dependent fashion. J Immunol 2007;177:4335-41
   Google Scholar
• Wollenberg A, Kraft S, Hanau D, Bieber T. Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema. J Invest Dermatol 1996;106:446-53
   PubMed Web of Science ®Google Scholar
• Novak N, Kraft S, Haberstok J, et al. A reducing microenvironment leads to the generation of FcepsilonRI high inflammatory dendritic epidermal cells (IDEC). J Invest Dermatol 2002;119:842-9
   Google Scholar
• Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006;117:411-17
   PubMed Web of Science ®Google Scholar
• Kasraie S, Niebuhr M, Baumert K, Werfel T. Functional effects of interleukin 31 in human primary keratinocytes. Allergy 2011;66:845-52
   PubMed Web of Science ®Google Scholar
• Stott B, Lavender P, Lehmann S, et al. Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation. J Allergy Clin Immunol 2013;132:446-54
   PubMed Web of Science ®Google Scholar
• Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med 2011;365:1315-27
   PubMed Web of Science ®Google Scholar
• Hudson TJ. Skin barrier function and allergic risk. Nat Genet 2006;38:399-400
   PubMed Web of Science ®Google Scholar
• Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol 2008;121:1337-43
   PubMed Web of Science ®Google Scholar
• Henderson J, Northstone K, Lee SP, et al. The burden of disease associated with filaggrin mutations: a population-based, longitudinal birth cohort study. J Allergy Clin Immunol 2008;121:872-7
   PubMed Web of Science ®Google Scholar
• Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 2007;120:150-5
   PubMed Web of Science ®Google Scholar
• Ogg G. Role of T cells in the pathogenesis of atopic dermatitis. Clin Exp Allergy 2009;39:310-16
   PubMed Web of Science ®Google Scholar
• Omori-Miyake M, Yamashita M, Tsunemi Y, et al. In vitro assessment of IL-4- or IL-13-mediated changes in the structural components of keratinocytes in mice and humans. J Invest Dermatol 2014;134:1342-50
   PubMed Web of Science ®Google Scholar
• Kim BE, Leung DY, Boguniewicz M, Howell MD. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol 2008;126:332-7
   PubMed Web of Science ®Google Scholar
• Hatano Y, Terashi H, Arakawa S, Katagiri K. Interleukin-4 suppresses the enhancement of ceramide synthesis and cutaneous permeability barrier functions induced by tumor necrosis factor-alpha and interferon-gamma in human epidermis. J Invest Dermatol 2005;124:786-92
   PubMed Web of Science ®Google Scholar
• Hatano Y, Adachi Y, Elias PM, et al. The Th2 cytokine, interleukin-4, abrogates the cohesion of normal stratum corneum in mice: implications for pathogenesis of atopic dermatitis. Exp Dermatol 2013;22:30-5
   PubMed Web of Science ®Google Scholar
• Morizane S, Yamasaki K, Kajita A, et al. TH2 cytokines increase kallikrein 7 expression and function in patients with atopic dermatitis. J All Clin Immunol 2012;130:259-61
   PubMed Web of Science ®Google Scholar
• Elias PM, Steinhoff M. Outside-to-Inside” (and now back to “outside”) pathogenic mechanisms in atopic dermatitis. J Invest Dermatol 2008;128:1067-70
   PubMed Web of Science ®Google Scholar
• Harder J, Bartels J, Christophers E, Schroder JM. Isolation and characterization of human beta -defensin-3, a novel human inducible peptide antibiotic. J Biol Chem 2001;276:5707-13
   PubMed Web of Science ®Google Scholar
• Duits LA, Ravensbergen B, Rademaker M, et al. Expression of beta-defensin 1 and 2 mRNA by human monocytes, macrophages and dendritic cells. Immunology 2002;106:517-25
   PubMed Web of Science ®Google Scholar
• Yang D, Chertov O, Bykovskaia SN, et al. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999;286:525-8
   PubMed Web of Science ®Google Scholar
• Oppenheim JJ, Biragyn A, Kwak LW, Yang D. Roles of antimicrobialpeptides such as defensins in innate and adaptive immunity. Ann Rheum Dis 2003;62(Suppl 2):ii17-21
   PubMedGoogle Scholar
• Schauber J, Gallo RL. Antimicrobial peptides and the skin immune defense system. J Allergy Clin Immunol 2009;124:R13-18
   PubMed Web of Science ®Google Scholar
• Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002;347:1151-60
   PubMed Web of Science ®Google Scholar
• Nomura I, Goleva E, Howell MD, et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 2003;171:3262-9
   PubMed Web of Science ®Google Scholar
• Howell MD, Novak N, Bieber T, et al. Interleukin-10 downregulates anti-microbial peptide expression in atopic dermatitis. J Invest Dermatol 2005;125:738-45
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Schauber J, Coda A, et al. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J 2006;20:2068-80
   PubMed Web of Science ®Google Scholar
• Boguniewicz M, Leung DY. Recent insights into atopic dermatitis and implications for management of infectious complications. J Allergy Clin Immunol 2010;125(1):4-13
   PubMed Web of Science ®Google Scholar
• Baker BS. The role of microorganisms in atopic dermatitis. Clin Exp Immunol 2006;144:1-9
   PubMed Web of Science ®Google Scholar
• Eyerich K, Pennino D, Scarponi C, et al. IL17 in atopic eczema: linking allergen-specific adaptive and microbial triggered innate immune response. J Allergy Clin Immunol 2009;123:59-66
   PubMed Web of Science ®Google Scholar
• Miajlovic H, Fallon PG, Irvine AD, Foster TJ. Effect of filaggrin breakdown products on growth of and protein expression by Staphylococcus aureus. J Allergy Clin Immunol 2010;126:1184-90
   PubMed Web of Science ®Google Scholar
• Kisich KO, Carspecken CW, Fieve S, et al. Defective killing of Staphylococcus aureus in atopic dermatitis is associated with reduced mobilization of human beta-defensin-3. J Allergy Clin Immunol 2008;122:62-8
   PubMed Web of Science ®Google Scholar
• Aberg KM, Man MQ, Gallo RL, et al. Co-regulation and interdependence of the mammalian epidermal permeability and antimicrobial barriers. J Invest Dermatol 2008;128:917-25
   PubMedGoogle Scholar
• Kabashima-Kubo R, Nakamura R, Sakabe J, et al. A group of atopic dermatitis without IgE elevation or barrier impairment shows a high Th1 frequency: possible immunological state of the intrinsic type. J Dermatol Sci 2012;67:37-43
   PubMed Web of Science ®Google Scholar
• Tokura Y. Extrinsic and intrinsic types of atopic dermatitis. J Dermatol Sci 2010;58:1-7
   PubMed Web of Science ®Google Scholar
• Kägi MK, Wüthrich B, Montano E, et al. Differential cytokine profiles in peripheral blood lymphocyte supernatants and skin biopsies from patients with different forms of atopic dermatitis, psoriasis and normal individuals. Allergy 2002;57:431-5
   Google Scholar
• Suarez-Farinas M, Dhingra N, Gittler J, et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol 2013;132:361-70
   PubMed Web of Science ®Google Scholar
• Jeong CW, Ahn KS, Rho NK, et al. Differential in vivo cytokine mRNA expression in lesional skin of intrinsic vs. extrinsic atopic dermatitis patients using semiquantitative RT-PCR. Clin Exp Allergy 2003;33:1717-24
   PubMed Web of Science ®Google Scholar
• von Kobyletzki G, Pieck C, Höxtermann S, et al. Circulating activation markers of severe atopic dermatitis following ultraviolet A1 cold light phototherapy: eosinophil cationic protein, soluble interleukin-2 receptor and soluble interleukin-4 receptor. Br J Dermatol 1999;140:966-8
   Google Scholar
• Choi JJ, Park BK, Song GY, et al. Establishment of an in vitro test system to evaluate the down-regulatory activities of natural products on IL-4. Arch Pharm Res 2007;30:1102-10
   Google Scholar
• Crocker IC, Townley RG, Khan MM. Phosphodiesterase inhibitors suppress proliferation of peripheral blood mononuclear cells and interleukin-4 and -5 secretion by human T-helper type 2 cells. J Invest Dermatol 1996;107:51-6
   Google Scholar
• Hanifin JM, Chan SC, Cheng JB, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. Clin Exp Med 2012;12:241-5
   Google Scholar
• Panahi Y, Davoudi SM, Madanchi N, Abolhasani E. Recombinant human interferon gamma in treatment of atopic dermatitis. Clin Exp Med 2012;12:241-5
   Google Scholar
• Chang TT, Stevens SR. Atopic dermatitis: the role of recombinant interferon-gamma therapy. Am J Clin Dermatol 2002;3:175-83
   PubMedGoogle Scholar
• Morioka T, Yamanaka K, Mori H, et al. IL-4/IL-13 antagonist DNA vaccination successfully suppresses Th2 type chronic dermatitis. Br J Dermatol 2009;160:1172-9
   Google Scholar
• Wenzel S, Ford L Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. New Engl J Med 2013;368:2455-66
   PubMed Web of Science ®Google Scholar
• Hijnen D, De Bruin-Weller M, Oosting B, et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T-cell-attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol 2004;113:334-40
   PubMed Web of Science ®Google Scholar
• Kimura T, Sugaya M, Suga H, et al. Variations in serum TARC and I-TAC levels reflect minor changes in disease activity and pruritus in atopic dermatitis. Acta Derm Venereol 2014;94(3):331-2
   PubMed Web of Science ®Google Scholar
• Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014;371:130-9
   PubMed Web of Science ®Google Scholar
• Lafyatis R. Targeting fibrosis in systemic sclerosis. Endocr Metab Immune Disord Drug Targets 2006;6:395-400
   Google Scholar
• Kanellakis P, Ditiatkovski M, Kostolias G, Bobik A. A pro-fibrotic role for interleukin-4 in cardiac pressure overload. Cardiovasc Res 2012;95(1):77-85
   Google Scholar